Advertisement
"Uroplasty looks forward to contributing in a meaningful way to theimportant public programming and advocacy that NAFC brings to the very largecommunity impacted by incontinence issues," said Uroplasty's President andChief Executive Officer, David Kaysen. "NAFC is an important resource forthose seeking solutions to incontinence and a voice for a meaningful publichealth debate around this problem; we plan to leverage our unique expertise tohelp this important organization continue its valuable work."
Advertisement
Uroplasty joins a team of thirteen other pharmaceutical, device, andmedical products companies which support NAFC's programs in public healtheducation, communications and collaboration with professional societies, andadvocacy.
An estimated 33 million people in the United States suffer from anoveractive bladder and an estimated 12.2 million of these adults have urgeincontinence.(1) Although overactive bladder is most common among older adultsand women, it does not discriminate. In fact, starting at age 60, men whoreport symptoms of overactive bladder begin to outnumber women who do so, withabout 42% of men over age 74 reporting symptoms compared with 32% of women inthe same age group.(2) Anyone, at any age, can suffer from the symptoms ofthis problem.
Uroplasty offers a pioneering procedure called the Urgent(R) PCNeuromodulation System, which is a proprietary, minimally invasive nervestimulation device designed for office-based treatment of urge incontinence,urinary urgency and urinary frequency, symptoms often associated withoveractive bladder. Application of neuromodulation therapy targets specificnerve tissue and disrupts the signals that lead to these symptoms. Uroplastysells the Urgent PC system in the United States, Canada, and countriesrecognizing the CE mark. Outside of the United States, Urgent PC is alsoindicated for the treatment of fecal incontinence.
For more information about the Urgent(R) PC Neuromodulation System, pleasecall 866-277-0466 or visit http://www.uroplasty.com.
About the National Association For Continence (NAFC)
The National Association For Continence is a 501(c)3 corporation whosemission is threefold: 1) to educate the public about the causes, diagnosiscategories, treatment options, and management alternatives for incontinence,voiding dysfunction, nocturnal enuresis, and related pelvic floor disorders;2) to network with other organizations and agencies to elevate the visibilityand priority given to these areas; and 3) to advocate on behalf of consumerswho suffer from such symptoms as a result of disease or other illness,obstetrical, surgical or other trauma, or deterioration due to the agingprocess itself. NAFC is broadly funded by consumers, healthcare professionalsand industry. It is the world's largest and most prolific consumer advocacyorganization devoted exclusively to this field. Visit http://www.nafc.org tolearn more.
About Uroplasty, Inc.
Uroplasty, Inc., headquartered in Minnetonka, Minnesota, with wholly ownedsubsidiaries in The Netherlands and the United Kingdom, is a medical devicecompany that develops, manufactures and markets innovative proprietaryproducts for the treatment of voiding dysfunctions. Our primary focus is thecommercialization of our Urgent PC system, which we believe is the onlyFDA-approved non-surgical neurostimulation therapy for the treatment ofurinary urgency, urinary frequency and urge incontinence, symptoms oftenassociated with a diagnosis of overactive bladder (OAB). We also offerMacroplastique(R) Implants, an injectable, minimally in
